drugset / Trial / NCT02273505

Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects

NCT02273505

Phase 1 Completed 20 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Comparative Pharmacokinetics of Asasantin Extended Release (ER) and of immediate release Persantin tablets combined with Acetyl salicylic acid (ASA) tablets

Timeline

Start
2000-04
Primary completion
2000-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dipyridamole Other / unclassified 100 mg
Subject Dipyridamole Other / unclassified 200 mg
Comparator Aspirin Small molecule 25 mg

Indications

No indication recorded.